４β－羥基睡茄內酯Ｅ化合物於製備供選擇性殺死口腔癌細胞之醫藥組成物之用途The application of selective killing of oral cancer cells involving 4β-hydroxywithanolide

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

102116128

專利證號

I 475987

專利獲證名稱

４β－羥基睡茄內酯Ｅ化合物於製備供選擇性殺死口腔癌細胞之醫藥組成物之用途The application of selective killing of oral cancer cells involving 4β-hydroxywithanolide

專利所屬機關 (申請機關)

高雄醫學大學

獲證日期

2015/03/11

技術說明

一種選擇性殺死口腔癌細胞之組合物，係選用對癌症細胞具有選擇性殺死機制之4β-羥基睡茄內酯E（4β-hydroxywithanolide E, 4βHWE）化合物，其萃取成本低廉，可有效提高產能，藉選擇性殺死口腔癌之特性，除了可節省治療時間之外，亦可減少傷害正常細胞而有較佳之安全性。本發明所提之4βHWE已建立標準純化步驟，製程穩定性高，不僅可單獨使用，亦可伴隨其他藥物使用。經由實驗萃取出之化合物4βHWE，已證實4βHWE係對癌症細胞有高敏感性，但對正常細胞較少傷害之藥物，將其應用在口腔癌患者，可增加口腔癌化學預防與治療時之效率。 We validate the potential of 4β-hydroxywithanolide (4βHWE) for selectively killing cancer cells and to elucidate its related mechanisms. The cost of this extraction is cheap and improved to demonstrate the selective killing to oral cancer cells. It can save the therapy time as well as reduce the potential side effect of general anticancer drugs to normal cells. The invetion set up the standard protocol for purification of 4βHWE in stable steps. This compound can single use as well as the combined treatments with other anticancer drugs. After our demonstration, we found that 4βHWE preferably cytotoxic to oral cancer cells but rather to normal oral cancer cells. It is a potential drug for antioral cancer drug to improve the chemoprevention and chemotherapy to oral cancer patients.

備註

連絡單位 (專責單位/部門名稱)

智財保護與科技管理組

連絡電話

07-3138030

網址